The aims to clarify the complexities of Homologous Recombination Deficiency (HRD) in cancer. This session will break down the science behind HRD, explaining its role in DNA repair and its impact on treatment response, particularly to PARP inhibitors. We’ll cover key concepts like BRCA mutations, genomic instability, and the Genomic Scar Score (GSS).